Logo Image
News
Media
Medical World NewsPodcastsVideosInsightsPeer ExchangeMedia DayNews NetworkRoundtablesShorts
Conference
Conference CoverageConference Listing
Publication
More
CME/CE
Partners
Resources
Interactive ToolsSpecial ProjectsSponsored
Contribute
Case StudiesWriters and Mentors
Clinical Forum Insights

Subscribe

  • News
  • Media
  • Conference
  • Publication
  • CME/CE
  • Partners
  • Resources
  • Contribute
  • Subscribe
  • Clinical Forum Insights
  • Antimicrobial Stewardship
  • Blood-Borne Diseases
    • Ebola
    • HCV / Hepatitis
  • Coronavirus / COVID
  • Food Borne Infection / Food Safety
    • E. Coli
    • Food Safety
    • Listeria
    • Salmonella
  • Fungal Infections
    • Candida auris
  • Gastrointestinal Infections
    • C. Difficile
    • H. Pylori
    • Norovirus
  • Healthcare Associated Infections (HAI)
  • Prevention
    • Antibiotics
    • Immunizations
    • Vaccines
  • Respiratory Infections
    • Community-Acquired Pneumonia
    • Measles
    • Influenza
  • Sexually Transmitted Diseases
    • HIV / AIDS
    • HPV
    • HSV
    • PrEP
  • Skin & Soft Tissue Diseases
    • MRSA
  • Zoonotic & Vector-Borne Diseases
    • Lyme Disease
    • ZIKA
Spotlight -
Vaccines in America|
Antibiotics Deconstructed|
Bench to Bedside With SIDP|
Antimicrobial Stewardship|
Hepatitis
Advertisement

Kevin Schwartz, MD, MSc, FRCPC

Advertisement

Articles by Kevin Schwartz, MD, MSc, FRCPC

"Antibiotic Never Events": The Ideal Target to Reduce Antimicrobial Exposure

ByBradley Langford, PharmD, BCPS*,Jennifer Lo, PharmD,Kevin Schwartz, MD, MSc, FRCPC
October 15th 2019

By stopping unnecessary antibiotics before they start, clinicians can avoid unnecessary harm to the patient and the population.

Advertisement

Latest Updated Articles

  • "Antibiotic Never Events": The Ideal Target to Reduce Antimicrobial Exposure
    "Antibiotic Never Events": The Ideal Target to Reduce Antimicrobial Exposure

    October 15th 2019



Advertisement
Advertisement

Trending on Contagion Live

1

IDSA Addresses Critical Questions on Staph aureus Bacteremia

2

Redefining HIV Management: Emerging Antiretroviral Drug Classes and Immunologic Strategies Shaping the Future of HIV Treatment, Prevention

3

FDA Says US Food Supply Safe as Cyclosporiasis Cases Top 11,000

4

H5N1: Have We Forgotten About Avian Influenza?

5

Bemnifosbuvir/Ruzasvir Meets Primary Endpoint in Phase 3 HCV Trial

  • About Us
  • Advertise
  • Editorial
  • Contact Us
  • Do Not Sell My Information
  • Privacy
  • Terms & Conditions
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

  • Contagion Live
  • CGT Live
  • Neurology Live
  • HCP Live
  • Oncology Live
  • Contemporary Pediatrics
  • Contemporary OBGYN
  • Urology Times
  • The Educated Patient
  • Patient Care Online
HCP Live Network
Brand Logo

© 2026 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us